A randomized controlled trial of Kangfuxin Liquid for diabetic peripheral neuropathy.
J EthnopharmacolJun 24, 2026 (epub)
Xiuqi Qiao, Li Liu, Zhuyi Jiang et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the efficacy and safety of Kangfuxin Liquid in patients with diabetic peripheral neuropathy (DPN). Seventy-three patients received either Kangfuxin Liquid or placebo for two weeks. The Kangfuxin group showed significant improvements in the total Toronto Clinical Neuropathy Score and sensory conduction velocity of the tibial nerve compared to placebo (P < 0.05).
Key findings
- Kangfuxin Liquid significantly reduced the total TCSS score compared to placebo.
- Sensory conduction velocity of the tibial nerve improved significantly in the Kangfuxin group.
- No significant differences in inflammatory markers or adverse events between groups.
- Only two cases of skin allergy were reported in the Kangfuxin group.
Why it matters
The findings suggest that Kangfuxin Liquid may be a beneficial adjunctive treatment for improving neuropathic symptoms and nerve conduction in patients with DPN, potentially enhancing patient quality of life.